Netramark Holdings Inc. — Board/Management Information 2021

Nov 30, 2021

Form 51-102F3

MATERIAL CHANGE REPORT

Item 1: Name and Address of Reporting Issuer

Nurosene Health Inc. (the “Company”) Suite 101 - 1655 Dupont Street Toronto, ON M6P 3T1

Item 2: Date of Material Change

November 21, 2021

Item 3: News Release

The news release announcing the material change was disseminated through Cision on November 22, 2021 and filed on SEDAR at www.sedar.com.

Item 4: Summary of Material Change

Nurosene Health Inc. ("Nurosene" or the "Company") announced that Kevin Taylor joined the Board of Directors of the Company and has been appointed the Chairman of the Board.

Item 5: Full Description of Material Change

The company announced that Kevin Taylor has joined the Board of Directors of the Company and has been appointed the Chairman of the Board.

Mr. Kevin Taylor is a seasoned executive with over 30 years of operating experience in Fortune 500 companies throughout North and South America. Mr. Taylor is currently the President and CEO of TEReI International Limited and was previously the President and General Manager of the carrier business of Nortel Networks Corporation ("Nortel") in the Caribbean and Latin American region responsible for $2B+ in revenue and 2000+ employees. Mr. Taylor graduated from Harvard Business School TGMP and received a Bachelor of Engineering - Science from the University of Western Ontario. Mr. Taylor acts as a director on a select number of public companies.

Mr. Taylor not only brings operational experience but personal life experience. Mental health is a very topical subject for Mr. Taylor, as he has witnessed first hand the struggles sadly losing his beloved wife and brother. Mr. Taylor has dedicated a significant amount of time mentoring and counselling with individuals who have found themselves in similar situations.

Kevin Taylor will come onto the Board of Directors and take over the duties from the current Chairman of the Board, Mark Smithyes, who has resigned from the Board. Mark Smithyes recently joined Nurosene in a full time operational role.

• 2 -

Item 6: Reliance on Subsection 7.1(2) of National Instrument 51-102– Continuous Disclosure Obligations

Not applicable.

Item 7: Omitted Information

Not applicable.

Item 8: Executive Officer

Blake Sing Chief Financial Officer investors@nurosene.com (416) 859-8838

Item 9: Date of Report

November 30, 2021

This material change contains "forward-looking information" within the meaning of applicable Canadian securities legislation which is based upon Nurosene's current internal expectations, estimates, projections, assumptions and beliefs, and views of future events. Forward-looking information can be identified by the use of forward-looking terminology such as "expect", "likely", "may", "will", "should", "intend", "anticipate", "potential", "proposed", "estimate" and other similar words, including negative and grammatical variations thereof, or statements that certain events or conditions "may", "would" or "will" happen, or by discussions of strategy. Forward-looking information includes estimates, plans, expectations, opinions, forecasts, projections, targets, guidance, or other statements that are not statements of fact. Specifically, this material change report contains forward-looking information relating to the Board of Directors of Nurosene and the appointment of Mr. Kevin Taylor as Chairman of the Board.

Any forward-looking information speaks only as of the date on which it is made, and, except as required by law, Nurosene does not undertake any obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise. New factors emerge from time to time, and it is not possible for Nurosene to predict all such factors. When considering these forward-looking statements, readers should keep in mind the risk factors and other cautionary statements in Nurosene's Final Long Form Prospectus dated May 20, 2021 and filed with the applicable Canadian securities regulatory authorities on SEDAR at www.sedar.com. The risk factors and other factors noted in Nurosene's Final Long Form Prospectus could cause actual events or results to differ materially from those described in any forward-looking information.